Home › Compound Library › Alfuzosin (Uroxatral)

Alfuzosin (Uroxatral)

Alpha Blockerprescriptionoral · inferred

Uroselective alpha-1 adrenergic receptor antagonist for benign prostatic hyperplasia. 10 mg PO once daily ER after a meal (food-sensitive absorption). Plasma half-life ~10h. Oral bioavailability ~49% with food. CYP3A4 metabolism — contraindicated with strong CYP3A4 inhibitors. Less orthostatic hypotension than non-selective alpha blockers (doxazosin, terazosin) because of apparent lower-urinary-tract selectivity. QT-prolongation caution at higher exposures.

Projected serum levels — 10 mg, once daily

Alfuzosin (Uroxatral)
Alfuzosin (Uroxatral) modeled serum levels, 10 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.50 1 1.5 2 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
Alfuzosin (Uroxatral) modeled serum levels with a loading dose of 12.8 mg, then 10 mg once daily The first dose is larger so levels approach steady state faster. 0 0.50 1 1.5 2 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 10 mg once daily (oral).

Loading schedule: 12.8 mg on day 1, then 10 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 1.2 mg, trough ≈ 0.41 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Alpha Blocker
Route modeled
Oral
Model confidence
inferred
Half-life
10 h
Common dose
10 mg
Suggested maximum
10 mg/day
Reference dose range
5–10 mg (single dose)
Suggested cadence
once daily
Validated against
10 mg oral — Cmax 0.014 mg/L at 8 h

Documented interactions

  • contraindicated
    Carbamazepine (Tegretol) + Alfuzosin (Uroxatral) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Alfuzosin (Uroxatral) AUC by ~0.20x

  • contraindicated
    Clarithromycin (Biaxin) + Alfuzosin (Uroxatral) CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change Alfuzosin (Uroxatral) AUC by ~10.00x

  • contraindicated
    Dasatinib (Sprycel) + Alfuzosin (Uroxatral) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Alfuzosin (Uroxatral) AUC by ~5.00x

  • contraindicated
    Diltiazem + Alfuzosin (Uroxatral) CYP inhibition

    Diltiazem mechanism_based of CYP3A4 predicted to change Alfuzosin (Uroxatral) AUC by ~10.00x

  • contraindicated
    Efavirenz (Sustiva) + Alfuzosin (Uroxatral) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Alfuzosin (Uroxatral) AUC by ~0.12x

  • contraindicated
    Grapefruit (whole fruit) + Alfuzosin (Uroxatral) CYP inhibition

    Grapefruit (whole fruit) mechanism_based of CYP3A4 predicted to change Alfuzosin (Uroxatral) AUC by ~10.00x

Serum checks 77 modeled interaction pairings for alfuzosin (uroxatral) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetics of alfuzosin, a new alpha 1-adrenoceptor antagonist, in healthy male volunteers Rouquier L et al. · British Journal of Clinical Pharmacology, 1994 DOI

    First-in-human PK study: oral bioavailability, food effect, and terminal half-life characterization supporting ER once-daily dosing.

  2. Alfuzosin 10 mg once daily in the management of acute urinary retention (ALF-ONE): results of a multicentre European study Roehrborn CG et al. · BJU International, 2006 DOI

    Large multicenter trial demonstrating alfuzosin 10 mg daily improves successful trial-without-catheter outcomes in men with AUR secondary to BPH.

2 published studies referenced in the app, each with a plain-language summary.